A Protocol for Constructing a Mouse Model of Hypertensive Myocardial Fibrosis Using Angiotensin II.

Area of Science:

• Cardiovascular Research
• Animal Models
• Fibrosis Research

Background:

• Continuous Angiotensin II (Ang II) infusion via osmotic pumps is standard for inducing hypertensive myocardial fibrosis in mice.
• Existing methods face challenges including Ang II instability, inaccurate pump placement, and lack of standardization.
• Limited detailed protocols hinder reproducible model establishment.

Purpose of the Study:

• To systematically optimize and standardize the Angiotensin II (Ang II) osmotic pump method for inducing hypertensive myocardial fibrosis in mice.
• To establish precise protocols for Ang II solution preparation, dosage calibration, pump implantation, and model evaluation.
• To validate a reliable and reproducible mouse model for studying hypertensive myocardial fibrosis.

Main Methods:

• Standardized preparation of Angiotensin II (Ang II) solutions.
• Calibrated dosage administration via subcutaneous osmotic pump implantation.
• Quantitative evaluation of myocardial fibrosis indicators, including blood pressure, cardiac function, and collagen deposition.

Main Results:

• Achieved high survival rates in Ang II osmotic pump-induced hypertensive myocardial fibrosis mouse models.
• Established stable systolic blood pressure (SBP) levels around 160 mmHg within seven days.
• Observed significantly reduced left ventricular ejection fraction, increased left ventricular end-diastolic dimensions, and elevated collagen deposition in myocardial tissues.

Conclusions:

• The optimized Angiotensin II (Ang II) osmotic pump protocol provides a feasible and reproducible method for establishing hypertensive myocardial fibrosis in mice.
• The developed quantitative phenotype verification system aids in consistent model assessment.
• This refined methodology supports further research into the mechanisms and treatment of hypertensive cardiac fibrosis.